All In Biotech

Drug Trial Radar · NCT00542178

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,472 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,472

Actual

Start

Oct 2003

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Sponsor type
NIH
Collaborators
National Eye Institute (NEI)
First posted
Oct 10, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.

Conditions

  • Diabetic Retinopathy

Interventions

  • Hypoglycemic AgentsDrug

    Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%

  • Standard glycemia controlDrug

    A strategy of glycemia drugs for HbA1c 7% - 7.9%

  • Intensive BP treatmentDrug

    A strategy of multiple BP agents to reduce SBP less than 120 mm Hg

  • Standard BP controlDrug

    A strategy of BP drugs for SBP less than 140 mm Hg

  • FenofibrateDrug

    Blinded fenofibrate

  • SimvastatinDrug

    Simvastatin 20-40 mg/d

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or VitrectomyTime frame: Measured at Year 4

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • The Berman Center for Clinical Research

    Minneapolis, Minnesota

  • Columbia University

    New York, New York

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Veterans Affairs

    Memphis, Tennessee

  • University of Washington

    Seattle, Washington

  • McMaster University

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.